NORTH BAY VILLAGE, Fla.--(BUSINESS WIRE)--July 14, 2006--Gary Macleod, Chief Executive Officer of NIMS (OTCBB:NIMU - News), announced that the Company received Certificates of Exportability (Section 801(e)(1) of Exportability) from the U.S. Food and Drug Administration (FDA) for international export of its patent protected AT-101 Motion Platform. The AT-101 is intended to be used for the temporary relief of musculoskeletal pains associated with osteoarthritis of the hip. Gary Macleod stated, “Many countries require these certificates prior to allowing importation of U.S. manufactured medical products.” He also added this action opens up markets for the AT-101 Motion Platform beyond the United States.
